+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

“Global Respiratory Inhalers market set to grow to $38bn by 2023” says new Visiongain report

24 October 2018
Pharma

Visiongain has launched a new pharma report: The Global Respiratory Inhalers Market Report : Dry Powder Inhalers, Single-dose DPI, Multi-dose DPI, Metered Dose Inhalers, Nebulizers, Jet Nebulizers, Ultrasonic Nebulizers, Vibrating-mesh Nebulizers, Asthma, COPD, Others.

Respiratory inhalers are used to relieve the symptoms of asthma and COPD and prevent exacerbations, which can lead to expensive hospital stays for patients and increase the risk of mortality. The increase in emission of air pollutants due to economic and industrial growth has made air quality an environmental problem of first order in many European and North American countries and it is now a growing problem in other parts of the world. Air pollution is convincingly associated with many signs of asthma aggravation. On the other hand, the prevalence of COPD is largely attributed to an increase in tobacco use, air pollution, and is also linked to the world’s ageing population, as the prevalence and morality of COPD increase with age. Thus, growing burden of respiratory diseases is likely to propel the growth of respiratory inhalers market.

The lead analyst of the report commented "The market is maturing with the launch of generic products expected during the forecast period. The launch of advanced products such as triple combination therapy and focus on development of e-devices are expected to drive the market growth. The emergence of connected devices - including inhalers, wearable sensors and mobile apps presents new growth opportunities."

Leading companies featured in the report include AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici S.p.A., GlaxoSmithKline (GSK), Merck & Co., Novartis, Teva.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biodefence Market Report 2023-2033

The global Biodefence market was valued at US$14,675.0 million in 2022 and is projected to grow at a CAGR of 7.78% during the forecast period 2023-2033.

13 January 2023

Read

Visiongain Publishes Neurotech Devices Market Report 2023-2033

The global Neurotech Devices market was valued at US$11,582.1 million in 2022 and is projected to grow at a CAGR of 13.78% during the forecast period 2023-2033.

12 January 2023

Read

Visiongain Publishes Wearable Brain Devices Market Report 2023-2033

The global Wearable Brain Devices market was valued at US$276.0 million in 2022 and is projected to grow at a CAGR of 11.4% during the forecast period 2023-2033.

03 January 2023

Read

Visiongain Publishes Asthma & COPD Therapies Market Report 2023-2033

The global Asthma & COPD Therapies market is estimated to be valued at US$47.85 billion in 2023 and is projected to grow at a CAGR of 7.31% during the forecast period 2023-2033.

30 December 2022

Read